Cargando…
Epigenetic modulation of immunotherapy and implications in head and neck cancer
Cancer progression is facilitated by distinct mechanisms developed by cancer cells to avoid immune recognition and clearance. The clinical application of immune checkpoint blockade (ICB), via monoclonal antibodies blocking PD-1/PD-L1 and CTLA4, has achieved promising durable therapeutic response in...
Autores principales: | Zhou, Liye, Xu, Na, Shibata, Hirofumi, Saloura, Vassiliki, Uppaluri, Ravindra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897200/ https://www.ncbi.nlm.nih.gov/pubmed/33403469 http://dx.doi.org/10.1007/s10555-020-09944-0 |
Ejemplares similares
-
Personalized cancer vaccination in head and neck cancer
por: Shibata, Hirofumi, et al.
Publicado: (2021) -
Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy
por: Shibata, Hirofumi, et al.
Publicado: (2021) -
Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma—backbone or add-on in immune-oncology?
por: Riess, Christin, et al.
Publicado: (2020) -
The promising alliance of anti-cancer electrochemotherapy with immunotherapy
por: Calvet, Christophe Y., et al.
Publicado: (2016) -
Epigenetic Modifiers as Novel Therapeutic Targets and a Systematic Review of Clinical Studies Investigating Epigenetic Inhibitors in Head and Neck Cancer
por: Burkitt, Kyunghee, et al.
Publicado: (2021)